Welcome to the Newsroom
02 March 2016
Prima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologic in EU Clinical Trial
· First-Ever Chinese-Manufactured Biologic Dosed in a European Clinical Trial· Prima BioMed Dosed First Patient in AIPAC Immuno-Oncology Trial in Metastatic Breast Cancer
SHANGHAI and SYDNEY, March 2, 2016 /PRNewswire/ -- WuXi Biologics Co. Ltd., a wholly owned subsidiary of WuXi AppTec Co. Ltd. (WuXi), and Prima BioMed Ltd. (Prima) (ASX: PRR; NASDAQ: PBMD), a leading immuno-oncology company, announced today that through their strategic supply partnership, Prima’s first-in-class immuno-oncology product candidate IMP321 (LAG-3 Ig fusion protein), manufactured at WuXi’s state-of-the-art cGMP facility in China, has now been dosed in a Phase IIb clinical trial in Belgium.
Article as pdf